Skip to main content
Radiation Oncology (London, England) logoLink to Radiation Oncology (London, England)
. 2014 Jun 25;9:140. doi: 10.1186/1748-717X-9-140

Correction: phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis -KOGC04-

Satoru Matsuda 1, Tsunehiro Takahashi 1,, Junichi Fukada 2, Kazumasa Fukuda 1, Hirofumi Kawakubo 1, Yoshiro Saikawa 1, Osamu Kawaguchi 2, Hiroya Takeuchi 1, Naoyuki Shigematsu 2, Yuko Kitagawa 1
PMCID: PMC4070087

Correction

After the publication of this work [1], we noted that owing to an inadvertent mistake, the description of the chemotherapy schedule shown in the Methods was different from that shown in the Abstract and the duration of S-1 treatment in the initial chemoradiotherapy was inadequately described in Figure 1. Therefore, Methods and Figure 1 were modified accordingly.

Figure 1.

Figure 1

Chemoradiotherapy consisted of combination chemotherapy with S-1, biweekly cisplatin, and fractionated radiation therapy.

In the “Chemoradiotherapy” section in the Methods, the 1st and 3rd paragraphs should read as follows:

“The chemoradiotherapy protocol consisted of administration of S-1 plus biweekly cisplatin and radiation (Figure 1). The initial chemoradiotherapy schedule was for 6 weeks: S-1 was orally administered twice daily from the evening of day 1 to the morning of day 15, and the total dose was based on the patient’s body surface area (BSA), as follows: <1.25 m2, 80 mg; 1.25–1.5 m2, 100 mg; and >1.5 m2, 120 mg. An escalating dose of cisplatin was administered by infusion over 1 h on days 1 and 15 without infusional hydration. The starting dose (level 1) of cisplatin was 15 mg/m2, the second dose (level 2) was 20 mg/m2, and the third dose (level 3) was 25 mg/m2.”

“After initial chemoradiotherapy, one cycle of combination chemotherapy with S-1 plus biweekly cisplatin was delivered. This consisted of 42 days of S-1 administered from the evening of day 1 to the morning of day 29 and of cisplatin administered on days 1, 15, and 29.”In “Figure 1,” based on the description in the manuscript, the duration of S-1 treatment in the initial chemoradiotherapy was revised to 1–15 days from 1–22 days (Figure 1).

Contributor Information

Satoru Matsuda, Email: s.matsuda1983@gmail.com.

Tsunehiro Takahashi, Email: surgeontsune@yahoo.co.jp.

Junichi Fukada, Email: fukada@rad.med.keio.ac.jp.

Kazumasa Fukuda, Email: fukudak@z6.keio.jp.

Hirofumi Kawakubo, Email: hkawakubo@z3.keio.jp.

Yoshiro Saikawa, Email: saiky@z8.keio.jp.

Osamu Kawaguchi, Email: kawaguti@rad.med.keio.ac.jp.

Hiroya Takeuchi, Email: htakeuchi@a6.keio.jp.

Naoyuki Shigematsu, Email: shige@rad.med.keio.ac.jp.

Yuko Kitagawa, Email: kitagawa@a3.keio.jp.

References

  1. Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04. Radiat Oncol. 2014;9:9. doi: 10.1186/1748-717X-9-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Radiation Oncology (London, England) are provided here courtesy of BMC

RESOURCES